EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation

Michael Perch iD, Paul Corris, Jim Lordan, Vasiliki Bessa, Jesper Magnusson iD, Geert M Verleden iD, Robin Vos iD, Nikolaus Kneidinger, Inga Leuckfeld, Erik Verschuuren, Jens Gottlieb iD

European Respiratory Journal · 2026-04 · 67 (4) · 2402154

DOI: 10.1183/13993003.02154-2024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 13.11.2025. Verfasst von Michael Perch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Section for Lung Transplantation, Rigshospitalet, Copenhagen, Denmark Michael.Perch@regionh.dk. Hauptthemen laut MEDLINE: Pyridones, Lung Transplantation, Bronchiolitis Obliterans, Antifibrotic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche Products.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic lung allograft dysfunction (CLAD) is a major obstacle to improving outcomes after lung transplantation. Bronchiolitis obliterans syndrome (BOS), characterised by progressive decline in forced expiratory volume in 1 s (FEV 1 ) due to fibrotic scarring of the small airways, accounts for most CLAD cases. Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, was assessed for treating progressive BOS.

Methods

An investigator-initiated, international, multicentre, randomised, double-blind, placebo-controlled phase II trial was conducted in nine European lung transplant centres. Adults with bilateral lung transplants and progressive BOS were randomised (1:1) to receive pirfenidone 2403 mg·day −1 or placebo with standard care for 26 weeks. The primary end-point was change in FEV 1 from baseline to week 26, with imputation for missing values.

Findings

From 1 May 2015 to 1 December 2019, 477 patients were screened, and 90 were randomised to pirfenidone (n=48) or placebo (n=42). Both groups showed continued decline in FEV 1 from baseline to week 26, with no significant difference in intention to treat (ITT), ITT with imputation, or per-protocol analyses. Secondary end-points (graft loss, death, re-transplantation) were similar between groups. Treatment-related serious adverse events were distributed equally.

Interpretation

Pirfenidone did not show superiority over placebo and standard care in this exploratory trial. It cannot be recommended for treating BOS. Further research is needed to explore other treatments for CLAD to improve long-term outcomes after lung transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesLung TransplantationBronchiolitis ObliteransAntifibrotic AgentsHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultForced Expiratory VolumeEuropeTreatment OutcomeBronchiolitis Obliterans Syndrome

Substanzen

PyridonespirfenidoneAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Cardiology, Section for Lung Transplantation, Rigshospitalet, Copenhagen, Denmark Michael.Perch@regionh.dk.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Translational and Clinical Science Institute Newcastle University, Newcastle upon Tyne, UK.
  • Freeman Hospital, Newcastle upon Tyne, UK.
  • Ruhrlandklinik, West German Lung Transplantation Center, University Hospital, University Duisburg-Essen, Essen, Germany.
  • Department of Pulmonology, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Michael Perch, Jesper Magnusson, Geert M Verleden, Robin Vos, Jens Gottlieb

Förderung

  • Roche Products

Zitieren

APA

Perch, M., Corris, P., Lordan, J., Bessa, V., Magnusson, J., Verleden, G. M., Vos, R., Kneidinger, N., Leuckfeld, I., Verschuuren, E., & Gottlieb, J. (2026). A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation. European Respiratory Journal, 67(4), 2402154. https://doi.org/10.1183/13993003.02154-2024

Vancouver

Perch M, Corris P, Lordan J, Bessa V, Magnusson J, Verleden GM, et al. A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation. European Respiratory Journal. 2026;67(4):2402154. doi:10.1183/13993003.02154-2024

BibTeX
@article{Perch2026,
  author = {Perch, Michael and Corris, Paul and Lordan, Jim and Bessa, Vasiliki and Magnusson, Jesper and Verleden, Geert M and Vos, Robin and Kneidinger, Nikolaus and Leuckfeld, Inga and Verschuuren, Erik and Gottlieb, Jens},
  title = {A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {4},
  pages = {2402154},
  doi = {10.1183/13993003.02154-2024}
}
Kostenlos starten →